机译:利妥昔单抗和化疗的成人Burkitt淋巴瘤/白血病的改善结果:大型前瞻性多中心试验的报告
Univ Hosp Dept Internal Med Hematol &
Oncol 2 D-60596 Frankfurt Germany;
Maria Sklodowska Curie Mem Inst &
Oncol Ctr Dept Lymphoid Malignancies Warsaw Poland;
Univ Hosp Dept Internal Med 3 Ulm Germany;
Univ Hosp Dept Internal Med 3 Ulm Germany;
Clin Grosshadern Dept Med 3 Munich Germany;
Clin Grosshadern Dept Med 3 Munich Germany;
Univ Hosp Dept Internal Med Hematol &
Oncol 2 D-60596 Frankfurt Germany;
Univ Hosp Dept Hematol &
Oncol Essen Germany;
Univ Hosp Dept Hematol &
Oncol Essen Germany;
Charite Campus Benjamin Franklin Dept Hematol Oncol &
Tumorimmunol Berlin Germany;
Heidelberg Univ Dept Internal Med 5 D-69115 Heidelberg Germany;
Univ Hosp Schleswig Holstein Dept Internal Med 2 Kiel Germany;
Univ Hosp Carl Gustav Carus Dept Internal Med 1 Dresden Germany;
Univ Bonn Dept Internal Med 3 Bonn Germany;
Univ Hosp Dept Med 2 Mainz Germany;
Clin Bremen Mitte Dept Internal Med 1 Bremen Germany;
Univ Hosp Dept Hematol Oncol Regensburg Germany;
Maria Sklodowska Curie Mem Inst &
Oncol Ctr Dept Lymphoid Malignancies Warsaw Poland;
Univ Hosp Inst Radiotherapy Erlangen Germany;
Univ Hosp Schleswig Holstein Dept Internal Med 2 Kiel Germany;
Univ Clin Inst Human Genet Dusseldorf Germany;
Charite Campus Benjamin Franklin Dept Hematol Oncol &
Tumorimmunol Berlin Germany;
Charite Campus Benjamin Franklin Dept Hematol Oncol &
Tumorimmunol Berlin Germany;
Univ Hosp Dept Internal Med Hematol &
Oncol 2 D-60596 Frankfurt Germany;
机译:利妥昔单抗和化疗的成人Burkitt淋巴瘤/白血病的改善结果:大型前瞻性多中心试验的报告
机译:晚期强化化疗不能改善成人急性淋巴细胞白血病强化化疗的效果。前瞻性多中心随机试验(PETHEMA ALL-89)的结果。西班牙血液学会|血液学
机译:Rituximab和剂量茂密的化疗为Burkitt淋巴瘤的成人:随机,受控,开放标签,第3期试验
机译:用Rituximab在高级初级耐火或渐进非霍奇金淋巴瘤(NHL)中的rituximab的自同毒性方法。第二次报告
机译:针对凋亡蛋白的X型抑制剂,克服B细胞淋巴瘤中的Rituximab /化疗抗性
机译:利妥昔单抗和化疗改善成人伯基特淋巴瘤/白血病的预后:一项大型前瞻性多中心试验的报告
机译:提高成人Burkitt淋巴瘤/白血病的结果及利妥昔单抗和化疗:大型前瞻性多中心试验的报告